Among patients with pancreatic ductal adenocarcinoma (PDAC), the use of gene signature-based subtyping may guide personalized therapy.
Dusquetide reduces the duration of severe oral mucositis (OM) by up to half.
Lartruvo (olaratumab) is now approved, in conjunction with doxorubicin, to treat patients with soft tissue sarcoma incurable with radiotherapy or surgery.
Fear of cancer recurrence seems to be a primary reason why breast cancer patients choose to have their cancer-free breast removed.
Women vaccinated with earlier versions of the human papillomavirus (HPV) vaccine may only need cervical cancer screening every five years.
Patients with double-hit lymphoma (DHL) or double-expressor lymphoma (DEL) have inferior outcomes following autologous stem cell transplantation (ASCT).
Although the development of kinase inhibitors coincides with revolutionized clinical outcomes, age disparities in survival remain substantial.
Atezolizumab (Tecentriq) is now approved by the FDA for the treatment of metastatic non-small cell lung cancer (NSCLC).
Maintenance therapy with norethandrolone improves survival of elderly patients with acute myeloid leukemia (AML) without increasing toxicity.
Adequate follow-up may be needed to prevent suicide among young cancer survivors.
Regorafenib shows clinical antitumor activity and improves progression-free survival (PFS) among patients with non-apidocytic soft tissue sarcoma.
Osimertinib demonstrated clinical activity among patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
Panobinostat may marginally improve overall survival among patients with relapsed or refractory multiple myeloma.
SBRT is a safe and efficacious treatment option for patients with non-small cell lung cancer (NSCLC) whose tumors measure at least 5 cm.
Veliparib in combination with carboplatin and paclitaxel was well tolerated but did not significantly improve overall response rate, survival.
Despite being privately insured, patients receiving chemotherapy without trastuzumab for breast cancer may pay as much as $8000 in out-of-pocket costs.
Proton pump inhibitors (PPIs) may reduce the efficacy of capecitabine as a treatment for gastroesophageal cancer.
Androgen deprivation therapy (ADT) for the treatment of prostate cancer may be associated with an increased risk for dementia.
Among patients with chronic myeloid leukemia (CML), the development of new somatic mutations predicts treatment failure with tyrosine kinase inhibitors (TKIs).
Addition of selumetinib to docetaxel did not significantly improve progression-free survival, overall survival, or the overall response rate.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- The Role of Microbes in Oncogenesis and the Treatment of Cancer
- The Undetermined Role of Sunscreen in Skin Cancer Prevention
- Lartruvo (Olaratumab) Offers New Promise for Patients With Soft Tissue Sarcoma
- Veliparib + Chemo Fails to Improve OS, PFS in Untreated NSCLC
- Study Examines Costs of Breast Cancer Chemotherapy Regimens